Thymic stromal lymphopoietin (TSLP) plays an important role in the differentiation and proliferation of Th2 cells, resulting in eosinophilic inflammation and numerous allergic diseases. Baicalein (1), a major component of Scutellaria baicalensis, was found to be the first small molecule to block TSLP signaling pathways. It inhibited effectively eosinophil infiltration in house dust mite-induced and ovalbuminchallenged mouse models. Structure-activity relationship studies identified compound 11a, a biphenyl flavanone analog, as a novel human TSLP inhibitor for the discovery and development of new antiallergic drugs.
The prevalence of allergic diseases such as asthma, atopic dermatitis and allergic rhinitis has been steadily increasing over the past few decades 1 , severely affecting the quality of life of millions of people worldwide. Allergic diseases are characterized by abnormal inflammatory responses to allergens due to an imbalance in T helper 1 (Th1) and Th2 cell responses and overproduction of Th2 cells 2, 3 . Th2-mediated inflammatory responses, triggered by activated dendritic cells (DCs), play a key role in the pathogenesis and maintenance of allergic diseases 4 . In response to tissue damage or exposure to various environmental allergens, epithelial cells release cytokines such as thymic stromal lymphopoietin (TSLP), interleukin-33 (IL-33) and IL-25 5, 6 . These cytokines activate DCs, which in turn stimulate the differentiation of naïve T cells into Th2 subset and secretion of IL-4 from T cells in lymphoid organs, leading to the production of immunoglobulin E (IgE) by B cells 4, 7 . Moreover, these cytokines activate group 2 innate lymphoid cells (ILC2 cells) 8, 9 , which release IL-13 for mucus secretion, as well as IL-9 and IL-5 for the recruitment of mast cells and eosinophils, respectively. These cytokines orchestrate allergic inflammation, resulting in the development of allergic diseases such as asthma and atopic dermatitis 7 .
Among these cytokines, TSLP, an IL-7-like cytokine, is recognized as a major pro-allergic cytokine in DC-mediated Th2 immune responses 10 . TSLP, primarily produced by epithelial cells, binds to its cognate receptor TSLPR (or cytokine receptor-like factor 2) 11 and IL-7Rα to initiate the signal transducer and activator of transcription 5 (STAT5) signaling pathway 12 , resulting in the development of Th2 cells and activation of type 2 immune cells 7, 13 . Modulation of TSLP/TSLPR signaling by a soluble TSLPR fragment fused to the Fc fragment of immunoglobulin (TSLPR-Ig) 14 or an anti-TSLP antibody 15 reduced eosinophilic airway inflammation and allergen-induced bronchoconstriction, alleviating the severity of allergic diseases. These data suggest that blocking TSLP signaling is a promising strategy for the control of allergic diseases. However, despite the pressing need for the discovery of anti-allergic drugs, there have been few reports on small molecule inhibitors targeting the TSLP signaling pathways 16, 17 .
anhydrase. When a small molecule binds to a protein within μM to mM range (medium to low-affinity), the intensities of the bound molecules are greatly reduced because of T 2 relaxation, whereas unbound compounds do not show a significant reduction. In addition, reduction in signal intensities is also seen with chemical exchange processes in millisecond order. Thus, comparison of the NMR signal intensities of compounds in the absence or presence of a protein provides valuable information on the binding properties of a compound to the target protein.
In the phosphate-buffered saline (PBS) buffer condition, 1D NMR signals of 1 were significantly broadened in the presence of hTSLP ( Fig. 2A vs. B) , whereas no signal broadening was observed following incubation with other proteins such as TSLPR and carbonic anhydrase ( Fig. 2E vs. F). Results showed that the signals of 1 completely disappeared in the presence of hTSLP upon the enhancement of T 2 relaxation using the CPMG pulse ( Fig. 2C vs. D) . However, these signals were minimally affected in the presence of hTSLPR or carbonic anhydrase ( Fig. 2G vs. H) . These results indicate that compound 1 potentially binds to hTSLP and inhibit the hTSLP/hTSLPR signaling pathway. The signal broadening effects of 1 by hTSLP were dose-dependent. The K d value of compound 1 was 50.3 μM (Fig. 2I,J) , calculated according to the method described by Miller et al. 22 . The pull-down assay was performed using a His-tagged hTSLPR and a FLAG-tagged hTSLP and determined by Western blotting (See Supporting Information). The amount of the FLAG-tagged hTSLP bound to the His-tagged hTSLPR was reduced in a dose-dependent manner with the addition of compound 1 (0, 10, 50, and 100 μM). In addition, we determined the K d value of compound 1 (27 μM) by microscale thermophoresis (See Supporting Information).
The binding site of 1 in hTSLP was confirmed using hydrogen-deuterium exchange (HDX)-MS. HDX-MS monitors the exchange between deuterium in the solvent and backbone amide hydrogen, which generally provides information on the binding of a compound to a protein 24, 25 . Following the addition of 1, the N-terminal half of the H1 helix in hTSLP showed decreased deuterium uptake as illustrated in Fig. 3A,B . As the N-terminal residue (FEKIKAAYLST) is positioned close to the hTSLPR, compound 1 might bind to the interface of the hTSLP-hTSLPR interaction. In order to identify the binding site of 1 on hTSLP, we performed chemical shift perturbation (CSP) experiments using 15 www.nature.com/scientificreports www.nature.com/scientificreports/ Furthermore, we analyzed the binding mode of 1 on the surface of hTSLP using molecular docking simulations. Computer-aided binding analysis of 1 and hTSLP revealed that 1 was bound to the positively charged pocket (Lys 49 and Arg 149) through its hydroxyl groups, and the B ring of 1 interacted with the hydrophobic Regions showing lower and constant deuterium uptake after binding of 1 are colored blue and grey, respectively, whereas hTSLPR is indicated in green. (B) Deuterium uptake level plot of the blue-colored region. (C) CSP in the 1 H-15 N HSQC spectrum of 15 N-labeled hTSLP in the presence (red) and absence (black) of 1 in 1:4 molar ratio. The expanded spectra for the amide signals of the residues Tyr 43, Leu 44, Asn 152, and Arg 153 were presented. (D) Mapping of the CSP results on the surface of hTSLP. Red and yellow color denotes strongly (CSP > 0.014) and weakly (0.011 < CSP < 0.014) perturbated residues, respectively. Compound 1 is shown as a stick model in cyan color. (E) Modeled structure of compound 1 bound in the pocket of hTSLP. The key residues of hTSLP interacting with compound 1 were denoted. Surface electrostatic potentials are shown in blue and red color for positive and negative charges, respectively.
www.nature.com/scientificreports www.nature.com/scientificreports/ residues including Tyr 43 and Leu 44 ( Fig. 3E ). Docking studies of 1 with hTSLP suggested that 1 bound to the hTSLPR-binding interface of hTSLP.
Compound 1 inhibited hTSLP-hTSLPR interaction and hTSLP signaling.
To understand the function of 1 in hTSLP signaling, we performed a series of bioassays. First, an ELISA was performed to determine the effect of 1 on the interaction between hTSLP and hTSLPR. We constructed vectors expressing hTSLP with the N-terminal FLAG tag (FLAG-hTSLP) and hTSLPR with C-terminal octa-histidine tag (hTSLPR-his). Compound 1 inhibited the interaction between hTSLP and hTSLPR in a dose-dependent manner as shown in Fig. 4A . In addition, we established a cell-based assay to monitor STAT5 phosphorylation in human mast cell line-1 (HMC-1) cells after stimulation with hTSLP. Treatment with hTSLP increased STAT5 phosphorylation, which was inhibited by 1 as shown in Fig. 4B . Western blot ( Fig. 4C ) analyses also showed the dose-dependent inhibition of STAT5 signaling by 1. These results demonstrated that 1 inhibited the interaction between hTSLP and hTSLPR, which further inhibited STAT5 phosphorylation in hTSLP-stimulated cells.
Compound 1 inhibited eosinophil infiltration in HDM-challenged mice.
To determine the effect of 1 on TSLP in vivo, we used a mouse model of airway inflammation, which is predominantly mediated by TSLP and Th2 cells 26 . Naïve mice receiving OVA-specific DO11.10 CD4 T cells were challenged with a mixture of house dust mite (HDM) and OVA for 3 days (Fig. 5A ). These mice were then treated with either PBS or 1 (200 μg/mL) on day 4, 6, and 8 as indicated. On day 11 after the first challenge, the mice were euthanized and analyzed for eosinophilic inflammation. Although the total number of leukocytes in the bronchoalveolar lavage fluid (BALF) was comparable to that in the PBS control ( Fig. 5B ), the number of eosinophils was substantially reduced in mice treated with 1 compared with the PBS-treated control ( Fig. 5C ). Since this model relies on the function of Th2 cells, we measured the number of allergen-specific T cells, which interestingly was not changed by compound 1 treatment ( Fig. 5D ).
Effect of compound 1 on pulmonary eosinophilia in OVA-sensitized and challenged mice.
To determine the effect of 1 on pulmonary eosinophilia in mice, a murine model of OVA-induced pulmonary eosinophilia was used ( Fig. 6A) [27] [28] [29] . Eosinophil-rich inflammation is the hallmark feature of both asthma in humans and allergic airway inflammation in mice 30 . A single intraperitoneal (IP) administration of 1 inhibited airway inflammation in a dose-dependent manner ( Fig. 6B ). At a dose of 100 mg/kg, the number of eosinophils recruited to the airways was significantly reduced. We further assessed the temporal relationship between the dose of 1 and Strategy for structural modification of compound 1. The biological evaluation of compound 1 suggested that targeting hTSLP signaling using small molecules is possible and could be a promising treatment option for allergic diseases. Based on the chemical structure of 1, the SAR studies focused on three purposes: to identify the essential OH groups, improve the physicochemical properties, and synthesize new analogs of 1. As shown in Fig. 7 , compound 1 was subdivided into three ring regions: A, B, and C. First, we aimed to investigate the necessity of the three hydroxyl groups in ring A of 1 for hTSLP inhibition. Second, we intended to introduce a biphenyl moiety instead of the phenyl group in ring B because hydrophobic amino acid residues were observed near the binding site of 1 to hTSLP in the in silico docking studies. Third, we attempted to elucidate the planarity of the ring C on hTSLP-binding. Reduction of the double bond between C-2 and C-3 carbons was expected to convert the planar flavone structure into a non-flat flavanone structure.
Analog synthesis of compound 1. In order to determine the importance of the hydroxyl groups in the A ring for hTSLP inhibition, we converted three OH groups of 1 into corresponding methoxy groups (2) by reacting 1 with methyl iodide in acetone 31 . The hTSLP inhibitory activities of 2 and commercial mono-hydroxylated flavones (3a-3c, Fig. 8 ) were measured using ELISA. None of the compounds showed >50% inhibition at 1 mM, suggesting that at least two OH groups are needed to block the interaction between hTSLP and hTLSPR (Table 3) .
Next, di-hydroxylated flavones (6a-6d) and flavanones (7a-7b) were synthesized in four or five steps from commercially available 2′-hydroxy-dimethoxyacetophenones and appropriate benzaldehydes ( Fig. 9 ). Briefly, condensation of acetophenone with benzaldehyde (benzaldehyde for 4a and 4c, and p-anisaldehyde for 4b and 4d) in THF under basic condition produced the corresponding chalcones 4a-4d in 64-98% yield. Treatment of 4a-4d with iodine powder in DMSO provided the flavone compounds 5a-5d in 38-78% yield 32 . Demethylation of 5a-5d was achieved by treating BBr 3 in CH 2 Cl 2 under reflux to afford the flavone analogs 6a-6d in 47-82% yield 33, 34 . Reaction temperature and maintenance of anhydrous reaction conditions were critical for the demethylation step. Reflux condition provided the desired fully-demethylated compounds 6a-6d while reaction at room temperature resulted in mono-demethylated compounds as major products. Hydrogenation of compounds 6a-6d was carried out in the presence of Pd/C and H 2 35 . The 5,7-dihydroxylated flavones (6a-6b) were converted into the corresponding flavanones (7a-7b) in 56-74% yield. However, the 6,7-dihydroxylated flavones (6c-6d) remained intact under the same condition. As the intramolecular hydrogen bonding between the OH group of the A ring and the carbonyl group of the B ring was significantly increased in the 5,7-dihydroxylated flavones, compounds 6a-6b were more reactive than the 6,7-dihydroxylated flavones 6c-6d towards catalytic hydrogenation. The conversion of the planar flavone to the non-flat flavanone structure was expected to affect hTSLP binding and physicochemical properties. Flavanone analogs showed weaker hTSLP-inhibitory activities www.nature.com/scientificreports www.nature.com/scientificreports/ than the corresponding flavones did (7a vs. 6a and 7b vs. 6b) as shown in Fig. 10 . However, the kinetic solubility of the flavanones (111 μM and 505 μM for 7a and 7b, respectively) in PBS was increased compared to that of the corresponding flavones (30 μM and 486 μM for 6a and 6b, respectively). Therefore, the flavanone scaffold could be utilized to improve the physicochemical properties of flavones.
To increase the hTSLP-binding affinity, a lipophilic ring-extended biphenyl group was introduced into the C ring region. Ring-extended compounds 10a-10i were obtained in two steps from bromoflavones 8a-8c ( Fig. 11 ), which contained a bromo group on the 3′-or 4′-position of B ring. They were prepared from www.nature.com/scientificreports www.nature.com/scientificreports/ 2′-hydroxy-dimethoxyacetophenones and bromobenzaldehydes by applying the synthetic procedure described in Fig. 9 . Reaction of 3′-bromoflavones (8a-8b) or 4′-bromoflavone (8c) with appropriate benzeneboronic acid (benzeneboronic acid for 9c and 9e, 4-fluorobenzeneboronic acid for 9d and 9f, 4-nitrobenezeneboronic acid for 9b and 9h, and 4-methoxybenzeneboronic acid for 9a, 9g, and 9i) in the presence of tetrakis(triphenylphosphine) palladium at 90 °C for 5 h afforded the biphenyl compounds 9a-9i in 23-78% yield. Demethylation of 9a-9i by treatment of BBr 3 under reflux for 12 h afforded the final compounds 10a-10i in 13-46% yield 33, 34 . Reduction of the C ring was attempted under hydrogenation conditions (Pd/C, H 2 ). Hydrogenation of 6,7-dihydroxylated biphenyl analogs (10e-10i) did not occur under this condition as observed with compounds 6c-6d and the starting materials were recovered. Among the 5,7-dihydroxylated biphenyl flavones (10a-10d), only compound 10a was reduced to provide compound 11a in 68% yield. The higher reactivity of compound 10a than the Table 3 . hTSLP-inhibitory activities of compounds (2 and 3a-3c) by ELISA. www.nature.com/scientificreports www.nature.com/scientificreports/ other 5,7-dihydroxylated analogs might be explained by the stability of its carbocation resonance structure (See Supporting Information). As the OH group of the biphenyl ring of 10a increased electron-releasing effect toward the C ring, the carbocation structure of 10a was more stabilized and the single-bond character between C-2 and C-3 was enhanced than that of the others. When acetic acid was added in the hydrogenation step to increase the reactivity of compounds 10b-10d, the flavanone ring was broken and no desired product was obtained.
Biphenyl-based flavones (10a-10i) showed increased TSLP-inhibitory activities compared to 1 (Fig. 12 ), which was used as the positive control in the ELISA assay. In particular, four compounds (10a, 10e, 10g, and 10h) exhibited >50% inhibition at 0.3 mM. The 6,7-dihydroxy analogs (10e-10h) displayed slightly stronger hTSLP-inhibition than that of the 5,7-dihydroxy analogs (10a-10d). In addition, the introduction of a phenyl group at the 3′-position of the B ring (10f) was more favorable for hTSLP binding than at the 4′-position of the B ring (10i). The combination of dihydroxyl groups on the 6-and 7-positions with the phenyl ring at the 3′-position of the B ring enhanced hTSLP-binding affinity compared to that of 1. Compounds 10e and 10g were the most potent biphenyl analogs with IC 50 values of 177 and 210 μM, respectively. Western blot analyses also showed that 10e and 10g inhibited STAT5 phosphorylation stronger than compound 1 (See Supporting Information). However, the solubility of the biphenyl compounds in PBS (pH 7.4) was much lower than that of compound 1.
Biphenyl-derived flavanone compounds were designed and expected to be more soluble in PBS than the corresponding flavones as observed with compounds 7a-7b. Catalytic hydrogenation of the C ring under traditional reduction condition (Pd/C, H 2 ) did not alter the 6,7-dihydroxylated biphenyl flavones (10e-10i) as expected. Only 10a was reduced to provide the flavanone analog 11a among 5,7-dihydroxylated analogs (10a-10d). The increased hydrophilicity of 11a compared with the flavone 10a was observed in reversed-phase HPLC experiments (16.15 min and 18.21 min for 11a and 10a, respectively Fig. 13A ). In addition, the kinetic aqueous solubility of 11a (66 μM) was comparable to that of 1 (62 μM). The IC 50 value of the flavanone 11a was 370 μM in the ELISA (Fig. 13B) , showing that it was slightly more potent than 1 (IC 50 = 460 μM). Furthermore, compound 11a strongly inhibited STAT5 phosphorylation even at 0.01 μM at the western blot experiment (Fig. 13C) . Therefore, the biphenyl-derived flavanone 11a which possesses moderate hTSLP-inhibition and good water solubility could be a prototype molecule for further structural modification in the development of novel hTSLP inhibitors. www.nature.com/scientificreports www.nature.com/scientificreports/
Conclusion
Recent studies of TSLP/TSLPR signaling pathways have demonstrated the key role of hTSLP in allergic immune responses. In this work, we identified compound 1, a flavonoid from S. baicalensis, as the first small molecule inhibitor of the hTSLP signaling pathway. In vitro studies including ELISA, flow cytometry, and Western-blot analysis showed that 1 blocked the interaction between hTSLP and hTSLPR in a dose-dependent manner. The HDX-MS experiment also confirmed that 1 binds to the hTSLPR-binding interface of hTSLP. In vivo studies in HDM-challenged mice showed that 1 substantially reduced eosinophilic inflammation. Furthermore, a single treatment with 1 effectively reduced eosinophil-rich pulmonary inflammation in the OVA-induced animal model. According to the SAR studies of compound 1, at least two OH groups in the A ring are required for hTSLP inhibition. Introduction of a hydrophobic biphenyl moiety in the B ring increased hTSLP-binding affinity. In addition, conversion of flavone into a flavanone structure in the C ring improved water solubility. Compound 11a was identified to be the most advanced hTSLP inhibitor in this series with moderate hTSLP-inhibition as well as good water solubility. Blocking hTSLP by using small molecule inhibitors may provide a new strategy to treat allergic diseases.
experimental procedures
General. All the chemicals and solvents used in the reaction were purchased from Sigma-Aldrich, TCI, or Alfa Aesar, and were used without further purification. Reactions were monitored by TLC on 0.25 mm Merck precoated silica gel plates (60-F 254 ). Reaction progress was monitored by TLC analysis using a UV lamp and/or KMnO 4 staining for detection purposes. Column chromatography was performed on silica gel (230-400 mesh, Merck, Darmstadt, Germany). NMR spectra were recorded at room temperature on either Bruker BioSpin Avance 300 MHz NMR or Bruker Ultrashield 600 MHz Plus spectrometer. Chemical shifts are reported in parts per million (ppm, δ) with TMS as an internal standard. Coupling constants are given in Hertz (Hz). Splitting patterns are indicated as s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad for 1 H NMR data. Mass spectra were obtained on an Agilent 6530 Accurate mass Q-TOF LC/MS spectrometer or an electrospray ionization PE Biosystems Sciex Api 150 EX mass spectrometer single quadruple equipped with a turbo ion spray interface. The purity of all final compounds was measured by analytical reversed-phase (RP) HPLC on an Agilent 1260 Infinity (Agilent) with a C18 column (Gemini-NX, 150 mm × 4.6 mm, 3 μm, 110 Å). RP-HPLC was performed using a linear gradient elution 50 to 100% of solvent B over 20 min (A = 0.1% TFA in water and B = 0.1% TFA in methanol). All compounds were eluted with a flow rate 0.5 mL/min and monitored at UV detector: 254 nm. Purity of final compounds was >95%.
HPLC Q-TOF/MS analysis. HPLC analysis was performed on a Shiseido CapCell PAK C18 column (5 µm, 4.6 mm I.D. × 150 mm) with a C18 guard column (4.00 × 3.00 mm; Phenomenex, Torrance, CA, USA). The flow rate was 0.6 mL/min, and injection volume was 10 µL. The mobile phase consisted of water containing 0.1% formic acid (A) and acetonitrile containing 0.1% formic acid (B). Gradient elution was as follows: 0-5 min, 10% B, 5-30 min, and 10-90% B. After UV detection, the eluted fractions were used for mass chromatography analysis. The elution fractions were ionized by ESI in positive mode, and MS and MS/MS spectrometric data were acquired in parallel alternating scan mode. The mass parameters were as follows: nebulizer pressure, 40 psi; capillary voltage, 4000 V; fragmentor voltage, 175 V; skimmer voltage, 65 V; drying gas temperature, 325 °C; flow rate of drying gas, 12.0 L/min; collision energy, 10, 20, and 30 V; mass scan range, m/z 50-1700. All acquisition parameters were adjusted using MassHunter Workstation software LC/MS Data Acquisition for 6530 series Q-TOF (version B.05.00).
Synthesis.
General procedure for chalcone synthesis. To a solution of 2′-hydroxy-4′,5′dimethoxyacetophenone or 2′-hydroxy-4′,6′-dimethoxyacetophenone in THF was added sodium methoxide (1.1 eq) in methanol solution at 0 °C and stirred for 20 min. Appropriate benzaldehyde (1.2 eq) was added to the reaction mixture at the same temperature. The mixture was stirred at room temperature for 8 h. The reaction mixture www.nature.com/scientificreports www.nature.com/scientificreports/ was partitioned and diluted with ethyl acetate (40 mL) and saturated ammonium chloride solution (40 mL). The organic layer was collected, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified using flash column chromatography or recrystallization with hexane-ethyl acetate to give the corresponding chalcones (4a-4d). General procedure for flavone synthesis. To a solution of chalcone in anhydrous DMSO was added iodine powder (1.1 eq) and stirred at 130 °C for 3 h. After being cooled to room temperature, the reaction mixture was diluted with ethyl acetate. The organic layer was washed with an aqueous solution of 0.1 M sodium thiosulfate, followed by the addition of brine. The organic layer was collected, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified by flash column chromatography to give flavones (5a-5d). General procedure for demethylation (6a-6d) . To a solution of flavones (5a-5b) in anhydrous dichloromethane was added boron tribromide (5 eq) per methoxy functional group at 0 °C under argon atmosphere. The reaction mixture was stirred under reflux for 12 h. After being cooled to room temperature, the reaction mixture was quenched with iced water and concentrated under reduced pressure. The residue was partitioned between ethyl acetate and water. The water layer was adjusted to pH 7 and extracted with ethyl acetate. The organic layer was collected, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified by flash column chromatography to give demethylated compounds (6a-6d). General procedure for the reduction of flavones to flavanones (7a-7b). To a solution of flavones (6a-6b) in a mixture of 1,4-dioxane and methanol (4:1) was added palladium on carbon (10%). The reaction mixture was purged with hydrogen gas and stirred at room temperature for 24 h. The reaction mixture was filtered through Celite pad and concentrated under reduced pressure. The residue was purified by flash column chromatography provided flavanone compounds (7a-7b). Brominated flavones (8a-8c) were synthesized by applying procedures for the synthesis of compound 5a from appropriate brominated chalcones. General procedure for the synthesis of biphenyl flavones (9a-9i). To a solution of bromoflavones (8a-8c) in toluene was added appropriate benzeneboronic acid (1.2 eq) and tetrakis(triphenylphosphine)palladium (0.1 eq) under argon atmosphere. To the reaction mixture was added cesium carbonate (2 M solution, 10%). The reaction mixture was stirred at 90 °C for 5 h. After being cooled at room temperature, the reaction mixture was partitioned between ethyl acetate and water. The combined organic layer was collected, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified by flash column chromatography to give biphenyl flavones (9a-g). General procedure for the synthesis of compounds (10a-10i) . The ring-extended flavone compounds were dissolved in anhydrous dichloromethane and was added boron tribromide (1 M solution, 5 eq per methoxy functional group) at 0 °C under argon atmosphere. The reaction mixture was stirred under reflux for 12 h. After being cooled to room temperature, the reaction mixture was concentrated under reduced pressure and was diluted with ethyl acetate and water. The combined water layer was adjusted to pH 7, and re-partitioned with ethyl acetate. The organic layer was collected, dried over magnesium sulfate, and concentrated under reduced pressure. The residue was purified by flash column chromatography to give final compounds (10a-10i). 
Measurement of kinetic aqueous solubility. Measurement of kinetic aqueous solubility was conducted
using syringeless filter device (Whatman UniPrep Syringeless Filter Device, 1 mL, PTFE membrane, 0.45 μm pore size, Cat. No. US113UORG) and high performance liquid chromatography (Thermo UltiMate 3000 HPLC system equipped with on-line degasser, quaternary pump, thermostatted auto-sampler, column compartment and diode array detector) device and Agilent Eclipse plus C18, 4.6 × 100 mm, 3.5 μm column. In brief, 10 mM stock solution of tested compounds was prepared in DMSO. 25 μL of the stock solution was added to a 1-mL uniprep vial containing 475 μL of 0.1 M potassium phosphate buffer (pH 7.4), and was shaken at 800 rpm for 90 min at room temperature. Following shaking, the mixture was filtered by slowly pressing the upper tube of the 1 mL Mini-Uniprep TM filter (PTFE membrane, 0.45 μm). 250 μL of the filtrate solution was then transferred to a HPLC vial containing equal volume of acetonitrile. Calibration samples for HPLC analysis were prepared using 10 mM DMSO stock solutions in 50 v/v% acetonitrile in deionized water or phosphate buffer (nominal concentrations: 500, 100, 20, 5, 1 and 0 μM. Diluted filtrate solutions and calibration samples were analyzed by HPLC. The solubility of the test samples was calculated by multiplying the measured concentration with the dilution factor.
Protein preparation using baculovirus expression vector system. The genes endoding FLAG (a peptide DYKDDDDK sequence motif)-tagged human TSLP with thrombin cleavage site at C-terminus (FLAG-hTSLP-thrombin) and human TSLPR with C-terminal octa-histidine tag (hTSLPR-His), were cloned into the pAB-bee-8 × His vector (AB vector, USA) to construct the plasmid transfer vectors, and the vectors were amplified in E. coli DH5α. The recombinant baculoviruses were generated by co-transfection of the plasmid transfer vectors and the linearized baculovirus genomic vector ProFold-ER1 (AB vector, USA) into the Spodoptera frugiperda (Sf-9) cells, (Invitrogen, USA). The recombinant baculoviruses were amplified in Sf-9 cells cultured in Sf-900 II SFM medium (Thermo Fisher Scientific Inc, USA). Thereafter, Trichoplusiani (High-Five cells) (Invitrogen, USA), cultured in ESF921 medium (Expression Systems, LLC, USA), were infected with the recombinant baculoviruses harboring hTSLP or hTSLPR gene to produce hTSLP or hTSLPR protein, respectively, which was secreted into the medium. The resulting proteins were loaded into a Ni-NTA HisTrap column (Qiagen, Germany) pre-equilibrated with buffer A (20 mM Tris-Cl, 200 mM NaCl at pH 8.0) and eluted with buffer B (20 mM Tris-Cl, 200 mM NaCl, 1 M Imidazole at pH 8.0). The octa-histidine tag was cleaved during dialysis by overnight incubation with thrombin in buffer A at 4 °C. After cleavage, proteins were concentrated by ultrafiltration (10,000 MWCO; Merck Millipore, Germany) and loaded onto a Superdex S75 gel-filtration column (16 mm/60 cm; GE healthcare, UK) pre-equilibrated with 20 mM Tris-Cl, 200 mM NaCl, and 1 mM dithiothreitol at pH 8.0. TSLP (29 159 127 131) , bacterial cells were grown in M9 minimal medium containing 15 N NH 4 Cl. Cells were further grown for 4 h at 37 °C after induction by 1M IPTG (isopropyl-β-D-thiogalactoside) when cell density (OD 600 ) reached 0.6. After harvested, cells were resuspended in lysis buffer (0.1M Tris pH 7.4, 0.3M sodium chloride, 1 mM β-mercaptoethanol, 0.1% TritonX100, and 0.1 mM phenylmethylsulfonyl fluoride). Cells were then disrupted by sonication in an ice bath, and centrifuged at 32,500 × g for 60 min at 4 °C. The pellet, containing the inclusion bodies, was re-suspended in 8 M urea, 50 mM sodium phosphate pH 6.8, 5 mM β-mercaptoethanol and sonicated as above. Insoluble material was removed by high speed centrifugation at 32,500 × g for 60 min at 4 °C. The supernatant was loaded into 5 mL of pre-equilibrated Ni-NTA (HisTrap; GE Healthcare) column with buffer A (8 M urea, 50 mM sodium phosphate pH 6.8, and 5 mM β-mercaptoethanol).
Protein Preparation for 2D NMR studies.

− Δ −
TSLP (29 159 127 131) was eluted out of the column by using buffer A containing 500 mM Imidazole at pH 4.5. Eluted inclusion bodies solution was added drop-wise into refolding buffer (100 mM Tris pH 7.4, 1M L-arginine, 5 mM reduced glutathione, 0.5 mM oxidized glutathione, and 0.2 mM phenylmethylsulfonyl fluoride) at 4 °C with rapid stirring. The final concentration of protein was less than 0.1 mg/mL. The hexa-histidine tag was cleaved by thrombin protease at 4 °C in dialysis buffer (20 mM Tris pH 7.4, 300 mM sodium chloride) for overnight. Refolded proteins were further purified by size-exclusion chromatography using a Superdex 75 column with 20 mM sodium phosphate pH 6.8, 50 mM sodium chloride, and 2.5 mM ethylenediaminetetraacetic acid).
www.nature.com/scientificreports www.nature.com/scientificreports/ Statistical analysis. Statistical analysis was performed using GraphPad Prism 5 (GraphPad Software, USA).
Two-tailed analysis of variance (ANOVA) and Student's t-test were performed to calculate statistical significance which was set at * for P < 0.05.
